Biphenyl oxadiazole derivatives as sphingosine-1-phosphate receptors modulators
AssigneeAllergan, Inc.
InventorsJanet A. Takeuchi, Ken Chow, Ling Li
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel biphenyl oxadiazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.
Claims7
A compound having Formula I, its individual enantiomers, individual diastereoisomers, and individual isomers, individual tautomers or a pharmaceutically acceptable salt thereof,
- R1 is C1-10 alkyl, C3-10 cycloalkyl, —OC1-10 alkyl, —OH, halogen, aryl, heterocycle;
- R2 is H, C1-10 alkyl, C3-10 cycloalkyl, —OC1-10 alkyl, —OH, halogen or nitrile;
- X is H, halogen, Q or Z;
- Q is —(CH2)nN(C2-10)alkylene-, —O(C2-10)alkylene- or —S(C2-10)alkylene-;
- n is 0, 1, 2, 3, 4 or 5;
- and
- Z is COOR, SO2NH2, OPO3H2 or —P(O)(R)OH;
- and
- R is H, C1-10 alkyl, C3-10 cycloalkyl.
A method of treating a disorder associated with sphingosine-1-phosphate receptor modulation, which comprises administering to a mammal in need thereof, a pharmaceutical composition comprising a therapeutically effective amount of at least one compound of Formula I
- R1 is C1-10 alkyl, C3-10 cycloalkyl, —OC1-10 alkyl, —OH, halogen, aryl, heterocycle;
- R2 is H, C1-10 alkyl, C3-10 cycloalkyl, —OC1-10 alkyl, —OH, halogen or nitrile;
- X is H, halogen, Q or Z;
- Q is —(CH2)nN(C2-10)alkylene-, —O(C2-10)alkylene- or —S(C2-10)alkylene-;
- n is 0, 1, 2, 3, 4 or 5;
- and
- Z is COOR, SO2NH2, OPO3H2 or —P(O)(R)OH;
- and
- R is H, C1-10 alkyl, C3-10 cycloalkyl.
Dependencies are inferred from the claim text.